Latest Platform Expansion News

Netwealth delivered a resilient March quarter with $4 billion in net inflows, pushing total funds under administration to $125.8 billion despite a 3.7% market dip. Growth in Managed Accounts and new intermediary relationships underpin ongoing momentum.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Freelancer Limited has delivered a landmark FY25 with record profitability, a major NASA contract win, and significant AI-driven growth across its marketplaces and payment services.

Xref Limited reported a 54% jump in annual recurring revenue and a 28% reduction in operational expenses in Q3 FY26, driven by strong platform adoption and strategic integrations with global HR partners.

Peppermint Innovation Limited reported a $1.27 million net loss for the half-year ending December 2025 while achieving key milestones including activation of national payment rails in the Philippines and settling a statutory demand that led to an ASX trading suspension.

Pureprofile Ltd reported a robust 14.2% increase in revenue and a 21.6% rise in net profit for H1 FY26, driven by international expansion and AI-powered platform growth. The company also announced a strategic acquisition to deepen its market research capabilities.

Freelancer Limited has reported a landmark FY25 with record net profit and revenue growth, powered by strong AI integration and strategic expansion across its core marketplaces.

Butn Limited has reported its fifth consecutive half-year of revenue growth, underpinned by a $100 million senior debt facility and expanding platform originations. Despite a statutory loss, the company’s operational momentum and strategic initiatives signal robust growth prospects.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Viva Leisure has reported a striking 168% jump in net profit after tax for HY2026, driven by strong revenue growth and a booming technology segment. The company’s strategic shift towards technology and network optimisation is paying off, with cash flow and membership numbers also on the rise.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

Praemium Limited reported a 14% year-on-year increase in total Funds Under Administration to $70.5 billion for Q2 FY26, completing the OneVue transition and seeing strong net inflows in its Spectrum and Powerwrap platforms.